These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 21189389)

  • 1. Cardiac troponin cutoffs: the importance of assay sensitivity and the patient population.
    Kavsak PA; Dhesy-Thind S
    J Clin Oncol; 2011 Mar; 29(7):e177; author reply e178-9. PubMed ID: 21189389
    [No Abstract]   [Full Text] [Related]  

  • 2. Troponin I as a predictor for trastuzumab-related cardiotoxicity: current data do not provide mechanistic insights or allow for incorporation into clinical practice.
    Goel S; Beith JM
    J Clin Oncol; 2011 Mar; 29(7):e175-6. PubMed ID: 21189375
    [No Abstract]   [Full Text] [Related]  

  • 3. Trastuzumab and breast cancer.
    Strasser F; Betticher DC; Suter TM
    N Engl J Med; 2001 Sep; 345(13):996. PubMed ID: 11575296
    [No Abstract]   [Full Text] [Related]  

  • 4. Troponin I, cardiac ventricular dysfunction and causal toxicity of chemotherapy drugs.
    Delval L
    Ann Oncol; 2002 Dec; 13(12):1952-3; author reply 1953. PubMed ID: 12453868
    [No Abstract]   [Full Text] [Related]  

  • 5. Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide.
    Feola M; Garrone O; Occelli M; Francini A; Biggi A; Visconti G; Albrile F; Bobbio M; Merlano M
    Int J Cardiol; 2011 Apr; 148(2):194-8. PubMed ID: 19945181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On the recovery of trastuzumab-related cardiac dysfunction.
    Gillham CM; Chalmers AC; Plowman PN
    Clin Oncol (R Coll Radiol); 2001; 13(2):146. PubMed ID: 11373881
    [No Abstract]   [Full Text] [Related]  

  • 7. Trastuzumab-induced cardiac dysfunction.
    Panjrath GS; Jain D
    Nucl Med Commun; 2007 Feb; 28(2):69-73. PubMed ID: 17198344
    [No Abstract]   [Full Text] [Related]  

  • 8. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation.
    Cardinale D; Colombo A; Torrisi R; Sandri MT; Civelli M; Salvatici M; Lamantia G; Colombo N; Cortinovis S; Dessanai MA; Nolè F; Veglia F; Cipolla CM
    J Clin Oncol; 2010 Sep; 28(25):3910-6. PubMed ID: 20679614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trastuzumab cardiac side effects: only time will tell.
    Levine MN
    J Clin Oncol; 2005 Nov; 23(31):7775-6. PubMed ID: 16258081
    [No Abstract]   [Full Text] [Related]  

  • 10. Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib.
    Morris PG; Chen C; Steingart R; Fleisher M; Lin N; Moy B; Come S; Sugarman S; Abbruzzi A; Lehman R; Patil S; Dickler M; McArthur HL; Winer E; Norton L; Hudis CA; Dang CT
    Clin Cancer Res; 2011 May; 17(10):3490-9. PubMed ID: 21372222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiotoxicity of trastuzumab in clinical practice.
    McArthur HL; Chia S
    N Engl J Med; 2007 Jul; 357(1):94-5. PubMed ID: 17611218
    [No Abstract]   [Full Text] [Related]  

  • 12. Exploratory analysis of cardiac biomarkers in women with normal cardiac function receiving trastuzumab for breast cancer.
    Goel S; Simes RJ; Beith JM
    Asia Pac J Clin Oncol; 2011 Sep; 7(3):276-80. PubMed ID: 21884439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cardiac troponin I cut-off: practice with the automated Immulite assay].
    Lavoinne A; Cauliez B
    Ann Biol Clin (Paris); 2003; 61(3):364-5. PubMed ID: 12825550
    [No Abstract]   [Full Text] [Related]  

  • 14. Management of trastuzumab-related cardiac dysfunction.
    Carver JR
    Prog Cardiovasc Dis; 2010; 53(2):130-9. PubMed ID: 20728700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study.
    Onitilo AA; Engel JM; Stankowski RV; Liang H; Berg RL; Doi SA
    Breast Cancer Res Treat; 2012 Jul; 134(1):291-8. PubMed ID: 22476854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of 10% coefficient of variation and 99th percentile cutoff of troponin I in serum and heparinized plasma using Access 2 and DxI 800.
    Song S; Suh B; Lee SG; Kim JH; Kwon OH
    Clin Chim Acta; 2009 Jan; 399(1-2):117-8. PubMed ID: 18835262
    [No Abstract]   [Full Text] [Related]  

  • 17. [Cardiotoxicity of trastuzumab of significance in the adjuvant treatment of breast cancer].
    Menke-van der Houven van Oordt CW; Fliervoet HJ; Mandigers CM; van Spronsen DJ
    Ned Tijdschr Geneeskd; 2008 Jan; 152(3):158-63. PubMed ID: 18271465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Troponin I provides insight into cardiotoxicity and the anthracycline-trastuzumab interaction.
    Ewer MS; Ewer SM
    J Clin Oncol; 2010 Sep; 28(25):3901-4. PubMed ID: 20679626
    [No Abstract]   [Full Text] [Related]  

  • 19. HER2-positive breast cancer: current treatment strategies.
    Perez EA; Baweja M
    Cancer Invest; 2008 Jul; 26(6):545-52. PubMed ID: 18584344
    [No Abstract]   [Full Text] [Related]  

  • 20. Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide.
    Kelly H; Kimmick G; Dees EC; Collichio F; Gatti L; Sawyer L; Ivanova A; Dressler L; Graham ML; Carey LA
    Clin Breast Cancer; 2006 Aug; 7(3):237-43. PubMed ID: 16942640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.